Researchers found violet-derived cyclotide enhances glioblastoma treatment efficacy, requiring less TMZ.

Researchers at Brain Chemistry Labs in Wyoming have found that the cyclotide kalata B1, derived from violets, enhances the efficacy of Temozolomide (TMZ) chemotherapy against glioblastoma, a severe brain cancer. A synthetic version of kalata B1 can reduce the dosage of TMZ needed to effectively kill glioblastoma cells by over ten-fold. This discovery may lead to more effective treatments, although further testing and clinical trials are still needed.

September 30, 2024
4 Articles

Further Reading